Report of Foreign Issuer (6-k)
March 06 2015 - 6:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March, 2015
Commission File Number
Novogen
Limited
(Translation of registrants name into English)
16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ¨
Note: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrants home country), or under the rules of the home country exchange on which the registrants securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrants security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ¨ No þ
If yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Novogen Limited (Registrant)
Lionel Mateo
Lionel Mateo
Company Secretary
Date 6 March 2015
|
|
|
|
|
ASX:NRT
NASDAQ:NVGN
Novogen Ltd (Company)
ABN 37 063 259 754
Capital Structure
Ordinary Shares on issue:
250 M
Board of
Directors Dr Graham Kelly
Chairman & Executive Director
Steve Coffey Non Executive Director
John OConnor
Non Executive Director
Prof Peter Gunning Non Executive Director |
|
PRESS RELEASE 6 March
2015 CANTRIXIL DATA TO BE PRESENTED AT TWO MAJOR CONFERENCES
Novogen today announces that Professor Gil Mor MD PhD from Yale Medical School will be
presenting pre-clinical data on the lead candidate product, Cantrixil, at two upcoming conferences.
The first is an oral presentation at the 62nd Society of Reproductive Investigation conference, March
25-28, Hilton San Francisco, CA. Professor Mors presentation will focus on the pre-clinical efficacy studies that justified the Companys decision to progress Cantrixil into the clinic for the treatment of abdominal carcinomatosis.
The second is a late-breaking poster at the annual American Association for Cancer
Research (AACR) conference, April 18-22, Pennsylvania Convention Center, Philadelphia, PA. The presentation will review mechanistic aspects of Cantrixil efficacy in ovarian cancer stem cells, and also detail in vivo data generated on Cantrixil in
Yales recurrent ovarian cancer carcinomatosis model that has informed the design of the Companys first-in-man clinical trial.
About Novogen Limited
Novogen is a public, drug-development company whose shares trade on both the Australian Securities Exchange (NRT) and NASDAQ (NVGN).
The Novogen Group includes a New Haven CT based joint venture company, CanTx Inc., with Yale University.
Novogen has two Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill
the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and
fatal destruction of the cancer cells cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued,
with the ultimate objective of employing both technologies as a unified approach to first-line therapy.
Further information is available on our website www.novogen.com |
For more information please contact:
|
|
|
Corporate Contact Dr. Graham Kelly
Executive Chairman & CEO Novogen Group
Graham.Kelly@novogen.com +61 (0) 2 9472 4100 |
|
Media Enquiries Cristyn Humphreys
Chief Operating Officer Novogen Group
Cristyn.Humphreys@novogen.com +61 (0) 2 9472
4111 |
Forward Looking Statement
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and section 21E of the
Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as expects, appear, intends, hopes, anticipates,
believes, could, should, would, may, target, evidences and estimates, and other similar expressions, but these words are not the exclusive means of
identifying such statements. Such statements include, but are not limited to any statements relating to the Companys drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the
Companys drug development program, including, but not limited to, CANTRIXIL, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and
uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Companys drug components, including, but not limited to CANTRIXIL, the ability of the
Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Companys drug compounds, including, but not limited to, CANTRIXIL, that could slow or prevent
products coming to market, the uncertainty of patent protection for the Companys intellectual property or trade secrets, including, but not limited to, the intellectual property relating to CANTRIXIL, and other risks detailed
from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on managements current expectations, but actual results
may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Apr 2023 to Apr 2024